Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of HP-5070 in primary palmar hyperhidrosis
jRCT2031200143Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of oxybutynin in focal hyperhidrosis (PFH) (2 cohorts), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Adverse events. Started Nov 2020; status: completed.
02
Drugs
oxybutynin
03
Conditions
focal hyperhidrosis (PFH)
Beyond the preview
Go deeper on jRCT2031200143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200143.